BWP
STML

Baldwin Wealth Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Baldwin Wealth Partners’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,100
Closed -$15K – 565
2020
Q1 		$15K Hold
3,100
– – ﹤0.01% 400
2019
Q4 		$33K Hold
3,100
– – ﹤0.01% 364
2019
Q3 		$32K Hold
3,100
– – ﹤0.01% 362
2019
Q2 		$47K Hold
3,100
– – 0.01% 315
2019
Q1 		$40K Hold
3,100
– – 0.01% 326
2018
Q4 		$29K Hold
3,100
– – ﹤0.01% 342
2018
Q3 		$51K Hold
3,100
– – 0.01% 311
2018
Q2 		$50K Hold
3,100
– – 0.01% 314
2018
Q1 		$47K Hold
3,100
– – 0.01% 307
2017
Q4 		$48K Hold
3,100
– – 0.01% 305
2017
Q3 		$34K Hold
3,100
– – 0.01% 320
2017
Q2 		$29K Hold
3,100
– – ﹤0.01% 346
2017
Q1 		$27K Hold
3,100
– – ﹤0.01% 348
2016
Q4 		$33K Buy
3,100
+1,100
+55% +$13.3K 0.01% 328
2016
Q3 		$22K Buy
+2,000
New +$16.3K ﹤0.01% 375

Baldwin Wealth Partners's STML Position: Q2 2020 in Review

Baldwin Wealth Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,100 shares — an estimated $15K sold.

Baldwin Wealth Partners first reported a position in STML in Q3 2016 and held it in 15 quarters. The position peaked at $51K in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Baldwin Wealth Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Baldwin Wealth Partners sold 3,100 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $15K.
  • Baldwin Wealth Partners first reported a position in Stemline Therapeutics, Inc. in Q3 2016 and held it in 15 quarters.
  • Baldwin Wealth Partners's Stemline Therapeutics, Inc. position peaked at $51K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Baldwin Wealth Partners's 13F filing for Q2 2020, filed 21 Jul 2020.